Kymera Therapeutics公司宣布,其研发的KT-621一期B组临床试验数据被选为美国皮肤病学会(AAD)年会上的重磅口头报告环节。这一突破性进展凸显了该疗法在皮肤病领域的潜力。
Kymera Therapeutics公司宣布,其研发的KT-621一期B组临床试验数据被选为美国皮肤病学会(AAD)年会上的重磅口头报告环节。这一突破性进展凸显了该疗法在皮肤病领域的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.